Cannvas MedTech, Pancreatic Cancer Canada sign content deal
Cannvas MedTech has signed a content agreement with Pancreatic Cancer Canada. Under the terms of the agreement, Cannvas will provide educational content regarding the use of cannabis as part of a patient's pancreatic cancer treatment. The first collection of content was released last month on the Cannvass.Me website to coincide with National Pancreatic Cancer Awareness Month. As the program progresses, the two organizations will collaborate on the development of additional original content aimed at patients and caregivers. This will include physician testimonials, patient experiences, research papers and educational courses about medical cannabis.
"Access to physician-backed education around cannabis is crucial for everyone, particularly for patients and caregivers struggling with a disease as frightening as pancreatic cancer," said Shawn Moniz, CEO of Cannvas MedTech. "Pancreatic Cancer Canada will be able to offer their community an online portal, powered by our platform, to share knowledge and experiences about the benefits of using medical cannabis as an alternative health care option, and through this partnership Cannvas will have access to greater research and data to better serve our users."